Drugs / isosulfan blue dye
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT02336737 | Jan → Dec 2015 | female breast carcinoma | Endomagnetics Inc | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT05859971 Background | Apr → Jun 2023 | breast cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/2 | NCT00932035 Background | Jun 2009 → May 2014 | breast cancer | City of Hope Medical Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isosulfan blue dye | “Patients receive isosulfan blue dye subcutaneously (SC)” NCT00932035 ↗ |
| Modality | Diagnostic / imaging agent | “isosulfan blue based lymphatic mapping” NCT00932035 ↗ |
| Route | Subcutaneous | “isosulfan blue dye subcutaneously (SC)” NCT00932035 ↗ |